Enalapril therapy significantly reduced blood pressure (p<0.05) and improved plasma glucose control, reducing the M value from 19.6 to 10.1 (p<0.01) in hypertensive diabetics.
Observational (n=9)
Does enalapril improve blood pressure, renal function, and glucose homeostasis in hypertensive patients with non-insulin-dependent diabetes mellitus?
Enalapril effectively reduces blood pressure while simultaneously improving renal blood flow and glucose homeostasis in patients with hypertension and type 2 diabetes.
Absolute Event Rate: 10.1% vs 19.6%
p-value: p=<0.01
The antihypertensive efficacy of enalapril and its effects on renal function and glucose homeostasis were investigated in 9 hypertensive patients with non-insulin-dependent diabetes mellitus. Enalapril therapy produced a significant fall in blood pressure (BP) (p less than 0.05) and a significant increase in renal blood flow (p less than 0.05) without a change in glomerular filtration rate. Furthermore, fasting plasma glucose was significantly reduced (p less than 0.01). Similarly, M value, as an index of plasma glucose control in diabetes, was significantly reduced from 19.6 to 10.1 (p less than 0.01). These findings suggested that the angiotensin-converting enzyme inhibitor enalapril was effective in reducing BP and improving renal function, and might improve glucose homeostasis in hypertensive diabetics.
Ueda et al. (Tue,) conducted a observational in Hypertension with non-insulin-dependent diabetes mellitus (n=9). Enalapril vs. Baseline was evaluated on M value (index of plasma glucose control) (p=<0.01). Enalapril therapy significantly reduced blood pressure (p<0.05) and improved plasma glucose control, reducing the M value from 19.6 to 10.1 (p<0.01) in hypertensive diabetics.